YU66502A - 5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza - Google Patents

5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza

Info

Publication number
YU66502A
YU66502A YU66502A YUP66502A YU66502A YU 66502 A YU66502 A YU 66502A YU 66502 A YU66502 A YU 66502A YU P66502 A YUP66502 A YU P66502A YU 66502 A YU66502 A YU 66502A
Authority
YU
Yugoslavia
Prior art keywords
so2nr4r5
compounds
hydrogen
alkylpyrido
pyrimidines
Prior art date
Application number
YU66502A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Richard John Booth
Ellen Myra Dobrusin
Peter Laurence Toogood
Scott Norman Vanderwel
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of YU66502A publication Critical patent/YU66502A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
YU66502A 2000-03-06 2001-01-29 5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza YU66502A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06

Publications (1)

Publication Number Publication Date
YU66502A true YU66502A (sh) 2005-09-19

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
YU66502A YU66502A (sh) 2000-03-06 2001-01-29 5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza

Country Status (36)

Country Link
EP (1) EP1268476A1 (ja)
JP (1) JP2003528101A (ja)
KR (1) KR20020075805A (ja)
CN (1) CN1422268A (ja)
AP (1) AP2002002643A0 (ja)
AR (1) AR034119A1 (ja)
AU (1) AU2001233028A1 (ja)
BG (1) BG107161A (ja)
BR (1) BR0109056A (ja)
CA (1) CA2401368A1 (ja)
CO (1) CO5280200A1 (ja)
CR (1) CR6736A (ja)
CZ (1) CZ20022929A3 (ja)
DZ (1) DZ3308A1 (ja)
EA (1) EA200200802A1 (ja)
EE (1) EE200200506A (ja)
GT (1) GT200100037A (ja)
HN (1) HN2001000040A (ja)
HR (1) HRP20020798A2 (ja)
HU (1) HUP0300136A2 (ja)
IL (1) IL151480A0 (ja)
IS (1) IS6524A (ja)
MA (1) MA26881A1 (ja)
MX (1) MXPA02008535A (ja)
NO (1) NO20024235L (ja)
NZ (1) NZ520962A (ja)
OA (1) OA12227A (ja)
PA (1) PA8513201A1 (ja)
PE (1) PE20011177A1 (ja)
PL (1) PL358271A1 (ja)
SK (1) SK12472002A3 (ja)
SV (1) SV2001000338A (ja)
TN (1) TNSN01036A1 (ja)
WO (1) WO2001070741A1 (ja)
YU (1) YU66502A (ja)
ZA (1) ZA200207110B (ja)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
DK1333833T3 (da) 2000-10-23 2011-12-12 Glaxosmithkline Llc Ny trisubstitueret 8H-pyridol[2,3-d]pyrimidin-7-on-forbindelse til behandling af CSBP/RK/p38-kinnasemedierede sygdomme
DK1361880T3 (da) * 2001-02-12 2006-01-23 Hoffmann La Roche 6-substituerede pyrido-pyrimidiner
JP4166991B2 (ja) * 2001-02-26 2008-10-15 田辺三菱製薬株式会社 ピリドピリミジンまたはナフチリジン誘導体
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
CA2473026C (en) * 2002-01-22 2011-05-03 Warner-Lambert Company Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
US7629350B2 (en) 2002-04-19 2009-12-08 Smithkline Beecham Corporation Compounds
CA2494061C (en) 2002-07-31 2011-06-14 Wayne R. Danter Protein tyrosine kinase inhibitors
EP1551824B1 (en) 2002-10-09 2007-12-12 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
BRPI0406809A (pt) * 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
AU2004289428B2 (en) 2003-11-13 2010-06-03 F. Hoffmann-La Roche Ag Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP2008510770A (ja) * 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｌｋ阻害剤としての新規プテリジノン
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
EP1856053A1 (en) 2005-01-14 2007-11-21 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
JP2008535822A (ja) 2005-03-25 2008-09-04 グラクソ グループ リミテッド 新規化合物
EA200702073A1 (ru) 2005-03-25 2008-12-30 Глэксо Груп Лимитед Способ получения пиридо[2,3-d]пиримидин-7-оновых и 3,4-дигидропиримидо[4,5-d]пиримидин-2(1н)-оновых производных
UY29439A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
NZ566903A (en) * 2005-10-07 2011-09-30 Exelixis Inc Pyrido (2,3-D) pyrimidinone compounds and their use as PI3 inhibitors
CA2624965A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
MY146420A (en) 2006-09-15 2012-08-15 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
AU2007311480A1 (en) * 2006-10-16 2008-04-24 Forma Therapeutics, Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
BRPI0809998B8 (pt) * 2007-04-03 2021-05-25 Array Biopharma Inc composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas
LT2168966T (lt) 2007-06-15 2017-01-10 Msd K.K. Bicikloanilino darinys
CA2695406A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
NZ586069A (en) 2007-12-19 2012-05-25 Amgen Inc Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
CA2719538C (en) * 2008-04-07 2014-03-18 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2350070A1 (en) 2008-09-30 2011-08-03 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k and mtor
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
US8372970B2 (en) * 2009-10-09 2013-02-12 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
WO2011075616A1 (en) 2009-12-18 2011-06-23 Temple University - Of The Commonwealth System Of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
UY33221A (es) 2010-02-09 2011-09-30 Univ California MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
EA022527B1 (ru) * 2010-08-05 2016-01-29 Темпл Юниверсити - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн 2-ЗАМЕЩЕННЫЕ-8-АЛКИЛ-7-ОКСО-7,8-ДИГИДРОПИРИДО[2,3-d]ПИРИМИДИН-6-КАРБОНИТРИЛЫ И ИХ ПРИМЕНЕНИЕ
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
PL2646448T3 (pl) 2010-11-29 2017-12-29 OSI Pharmaceuticals, LLC Makrocykliczne inhibitory kinazy
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
SG193580A1 (en) 2011-03-23 2013-10-30 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
MX347040B (es) * 2011-05-17 2017-04-10 Principia Biopharma Inc Inhibidores de tirosina-cinasas.
US9718821B2 (en) 2012-02-23 2017-08-01 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
EP2958916B1 (en) * 2013-02-21 2018-09-12 Pfizer Inc Solid forms of a selective cdk4/6 inhibitor
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
WO2016015598A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
RS61934B1 (sr) 2016-08-15 2021-07-30 Pfizer Inhibitori piridopirimdinona cdk2/ 4/6
WO2018160076A1 (en) * 2017-03-03 2018-09-07 Auckland Uniservices Limited Fgfr kinase inhibitors and pharmaceutical uses
MA51846A (fr) 2018-02-15 2021-04-21 Nuvation Bio Inc Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
WO2020114519A1 (zh) * 2018-12-07 2020-06-11 杭州英创医药科技有限公司 作为cdk-hdac双通路抑制剂的杂环化合物
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
AU2022234998A1 (en) * 2021-03-08 2023-10-12 Jinan University Pyridopyrimidine compounds and applications thereof
WO2024056091A1 (zh) * 2022-09-16 2024-03-21 华东师范大学 作为rsk抑制剂的吡啶酮并嘧啶衍生物及其应用
WO2024099403A1 (zh) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 一种具有软药性质的硫醚类化合物、药物组合物及其用途
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
JP2001509805A (ja) * 1997-02-05 2001-07-24 ワーナー−ランバート・コンパニー 細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン
KR20010043829A (ko) * 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 비시클릭 피리미딘 및 비시클릭3,4-디히드로피리미딘

Also Published As

Publication number Publication date
PL358271A1 (en) 2004-08-09
HRP20020798A2 (en) 2004-02-29
EP1268476A1 (en) 2003-01-02
CR6736A (es) 2004-03-10
TNSN01036A1 (en) 2005-11-10
AP2002002643A0 (en) 2002-12-31
CN1422268A (zh) 2003-06-04
MA26881A1 (fr) 2004-12-20
BG107161A (en) 2003-06-30
IL151480A0 (en) 2003-04-10
HUP0300136A2 (en) 2003-05-28
CA2401368A1 (en) 2001-09-27
OA12227A (en) 2004-03-18
NZ520962A (en) 2003-09-26
EE200200506A (et) 2004-02-16
NO20024235D0 (no) 2002-09-05
CO5280200A1 (es) 2003-05-30
PA8513201A1 (es) 2003-06-30
BR0109056A (pt) 2003-06-03
SK12472002A3 (sk) 2003-04-01
KR20020075805A (ko) 2002-10-05
AR034119A1 (es) 2004-02-04
PE20011177A1 (es) 2001-11-23
DZ3308A1 (fr) 2001-09-27
HN2001000040A (es) 2001-09-06
SV2001000338A (es) 2001-11-30
JP2003528101A (ja) 2003-09-24
NO20024235L (no) 2002-11-05
MXPA02008535A (es) 2002-12-13
IS6524A (is) 2002-08-23
WO2001070741A1 (en) 2001-09-27
GT200100037A (es) 2002-03-04
ZA200207110B (en) 2003-12-04
EA200200802A1 (ru) 2003-02-27
CZ20022929A3 (cs) 2003-02-12
AU2001233028A1 (en) 2001-10-03

Similar Documents

Publication Publication Date Title
YU66502A (sh) 5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza
YU73300A (sh) Biciklični pirimidini i biciklični 3,4-dihidropirimidini kao inhibitori ćelijske proliferacije
KR101917972B1 (ko) ERK 억제제로서 티에노[2,3-c]피롤-4-온 유도체
TR200102001T2 (tr) P38 kinaz inhibitörleri olarak sübstitüe edilmiş pirazoller
YU50402A (sh) Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze
GEP20063915B (en) PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
DK0783505T3 (da) Pyrrolo[2,3-d]pyrimidiner og deres anvendelse
PE20020305A1 (es) 2-(4-PIRIDIL) AMINO-6-DIALCOXIFENIL-PIRIDO [2,3-d] PIRIMIDIN-7-ONAS COMO INHIBIDORES DE LA TIROSINA QUINASA
NO20000702D0 (no) cGMP PDE-inhibitorer for behandling av erektil dysfunksjon
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
UY27198A1 (es) Nuevos compuestos antiinflamatorios de bencimidazol
MXPA05013349A (es) Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
PE20020976A1 (es) Pirido-pirimidinas 6-sustituidas como inhibidores de quinasas
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
BR9909808A (pt) Pirazolopirimidinonas inibidoras de cgmp pde5 para o tratamento da disfunção sexual
AR053662A1 (es) Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
TNSN05188A1 (en) 4-aminopyrimidine-5-one
PE20020524A1 (es) 7-oxo-piridopirimidinas como inhibidores de quinasas
ATE353651T1 (de) 3-furylanaloga von toxoflavin als kinaseinhibitoren
PT1303512E (pt) Processo para a preparacao de arilacetilaminotiazoles
UA87895C2 (en) Substituted 5-phenyl pyrimidines i in therapy
DK157781A (da) Thiazolderivater fremgangsmaade til deres fremstilling samt deres anvendelse
MX2023012427A (es) Proceso mejorado para la preparacion de derivados de 7-(morfolinil)-2-(n-piperazinil) metiltieno [2,3-c] piridina.
TH65335A (th) สารประกอบพรัยโรโล [2,3d] ไพริมิดิน